-(vinkuliert)-logo.png "STADA Arzneimittel logo")
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates in two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxon for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Omeprazol for gastric ulcer/reflux.
Read More…
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone49-6101-6030
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.61 billion
Profitability
Miscellaneous
Employees10,416
Next Earnings Date6/27/2019 (Estimated)
OptionableNot Optionable
STADA Arzneimittel (OTCMKTS:STDAF) Frequently Asked Questions
What is STADA Arzneimittel's stock symbol?
STADA Arzneimittel trades on the OTCMKTS under the ticker symbol "STDAF."
When is STADA Arzneimittel's next earnings date?
Has STADA Arzneimittel been receiving favorable news coverage?
News articles about STDAF stock have trended very negative on Monday, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. STADA Arzneimittel earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the next several days. View News Stories for STADA Arzneimittel.
Who are some of STADA Arzneimittel's key competitors?
Some companies that are related to STADA Arzneimittel include Canopy Growth (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), Tilray (TLRY), USANA Health Sciences (USNA), CV Sciences (CVSI), Chromadex (CDXC), Canopy Rivers (RIV), Foamix Pharmaceuticals (FOMX), Natural Alternatives International (NAII), Mediwound (MDWD), True Drinks (TRUU), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD) and Cyanotech (CYAN).
Who are STADA Arzneimittel's key executives?
STADA Arzneimittel's management team includes the folowing people:
- Mr. Mark Burgess Keatley MBA, MA, MPhil, CFO & Member of Exec. Board (Age 62)
- Mr. Peter Goldschmidt, Chairman of the Exec. Board & CEO (Age 55)
- Mr. Miguel Pagan Fernandez, CTO & Member of Exec. Board (Age 54)
- Mr. Sebastian Kramer-Bach, Exec. VP of Corp. Communication (Age 44)
- Ms. Kay Reubelt, Director of Investor Relations
How do I buy shares of STADA Arzneimittel?
Shares of STDAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is STADA Arzneimittel's stock price today?
One share of STDAF stock can currently be purchased for approximately $90.37.
What is STADA Arzneimittel's official website?
How can I contact STADA Arzneimittel?
STADA Arzneimittel's mailing address is Stadastrasse 2-18, Bad Vilbel 2M, 61118. The company can be reached via phone at 49-6101-6030.
MarketBeat Community Rating for STADA Arzneimittel (OTCMKTS STDAF)
MarketBeat's community ratings are surveys of what our community members think about STADA Arzneimittel and other stocks. Vote "Outperform" if you believe STDAF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STDAF will underperform the S&P 500 over the long term. You may vote once every thirty days.
